Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT_6 partial agonist in rats by Jastrzębska-Więsek, Magdalena et al.
ORIGINAL ARTICLE
Study of a mechanism responsible for potential antidepressant
activity of EMD 386088, a 5-HT6 partial agonist in rats
Magdalena Jastrzębska-Więsek1 & Agata Siwek2 & Anna Partyka1 &
Lucyna Antkiewicz-Michaluk3 & Jerzy Michaluk3 & Irena Romańska3 &
Marcin Kołaczkowski4,5 & Anna Wesołowska1
Received: 21 January 2016 /Accepted: 6 April 2016 /Published online: 23 April 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract It was shown that 5-HT6 receptor agonists can exert
pharmacological activity due to various modifications in
monoamines’ level and metabolism activity in rats’ brain
structures. This finding was correlated with antidepressant-
or anxiolytic-like properties of these compounds. The study
was designed to establish a possible mechanism of the
antidepressant-like activity of the partial 5-HT6 receptor ago-
nist EMD386088 (5-chloro-2-methyl-3-(1,2,3,6-tetrahydro-4-
pyridinyl)-1H-indole hydrochloride) in rats. The concentra-
tions of monoamines (dopamine (DA), noradrenaline (NA),
and serotonin (5-HT)) and the rate of their metabolism were
measured ex vivo in the brain structures (hippocampus, nucle-
us accumbens, striatum) using high-performance liquid chro-
matography (HPLC). The rats were killed after the forced
swim test (FST); the collected tissue samples were used to
ex vivo experiments. The potency of EMD386088 to block-
ade dopamine transporter (DAT) was tested in a functional in
vitro study. FSTwas used to assess the involvement of D1- and
D2-like receptor subfamilies in antidepressant-like properties
of EMD386088. Neurochemical data from ex vivo
experiments showed that antiimmobility activity of
EMD386088 may be connected with the activation of dopa-
minergic system, while neither noradrenergic nor serotonergic
ones are involved in its effect. EMD386088 also possesses a
significant affinity for DATwhich may be a mechanism in the
abovementioned effect. Behavioral data seem to confirm the
importance of dopaminergic system activation in
antidepressant-like activity of EMD386088, since this effect,
observed in the FST, was abolished by the preferential D1- and
D2-like receptor subfamily antagonists SCH23390 and
sulpiride, respectively. Dopaminergic system is involved in
antidepressant-like activity of EMD386088.
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Introduction
A large amount of information has been collected in recent years
on serotonin (5-hydroxytryptamine, 5-HT) 5-HT6 receptors and
their possible physiological role within the central nervous sys-
tem (CNS). The 5-HT6 receptor mRNA expression and receptor
protein are largely confined to CNS, specifically striatum, nu-
cleus accumbens (NAc), olfactory tubercle, cortex, and hippo-
campus (Kohen et al. 1996; Gérard et al. 1996, 1997; Roberts
et al. 2002). Such specific localization in the CNS has suggested
that ligands of this receptor may be involved in regulating mood
changes (Monsma et al. 1993; Kohen et al. 2001; Wesołowska
and Jastrzębska-Więsek 2011), thus the 5-HT6 receptor has
emerged as an interesting molecular target for the development
of drugs useful in mood disorders. Moreover, there is still an
unresolved paradox that agonists/partial agonists and antago-
nists of this receptor evoke similar effects, i.e., procognitive
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(Fone 2008), antiobesity (Heal et al. 2008), anxiolytic, and an-
tidepressant (Svenningsson et al. 2007;Wesołowska et al. 2007;
Wesołowska 2008; Hirano et al. 2009; Carr et al. 2011;
Nikiforuk et al. 2011; Jastrzębska-Więsek et al. 2014, 2015).
According to Gérard et al. (1997), 5-HT6 receptors are
located outside 5-HT neurons, and are not autoreceptors.
Ward et al. (1995) found that 5-HT6 receptor mRNA projec-
tion fields rather in regions of 5-HT-containing cell bodies,
suggesting postsynaptic localization of these receptors.
In vivo microdialysis studies that were carried out have re-
vealed that both 5-HT6 receptor antagonists and agonists can
modulate the levels of a variety of neurotransmitters in several
brain regions associated with learning and memory and mood
changes. A systemic administration of 5-HT6 receptor antag-
onists (e.g., SB 271046) has been shown to increase the re-
lease of acetylcholine and glutamate in the frontal cortex and
dorsal hippocampus (Dawson et al. 2001; Riemer et al. 2003).
In addition, the 5-HT6 receptor agonist, WAY-181,187, can
elicit robust elevations in extracellular concentrations of γ-
aminobutyric acid (GABA) in the dorsal hippocampus with-
out affecting the release of noradrenaline (NA), 5-HT, dopa-
mine (DA), or glutamate (Schechter et al. 2008). These data
are consistent with the localization of 5-HT6 receptors in
GABAergic interneurons suggested by colocalization of the
receptor with the neuronal form of glutamic acid decarboxyl-
ase, GAD67, suggesting an indirect modulation of hippocam-
pal glutamatergic neurotransmission via 5-HT6 receptor
antagonist-mediated disinhibition (Ward and Dorsa 1996;
Woolley et al. 2004). ST 1936, another 5-HT6 receptor agonist
increased dialyzate DA and NA in the shell of NAc and in the
medial prefrontal cortex (mPFX); it did not bind to the nor-
adrenaline transporter (NET) and dopamine transporter (DAT)
(Borsini et al. 2008; Valentini et al. 2011). As mentioned
above, the scientific priority is to focus on finding information
about these ligands and the differences in their effects/
mechanisms of action. Studies conducted with EMD
386088, a 5-HT6 receptor partial agonist (Jastrzębska-
Więsek et al. 2013) and a tool substance, fit well in this current
research.
The systemic administration of EMD 386088, follow-
ing acute and three times in 24-h treatment, caused an
antidepressant-like effect detected during the modified
forced swim test (FST) in rats. This effect of EMD
386088 was blocked by the selective 5-HT6 receptor
antagonist SB 271046 administered in an inactive dose.
Furthermore, its antidepressant-like effect, mediated di-
rectly by stimulation of 5-HT6 receptors, seems to be
specific, since EMD 386088 did not affect rats’ locomo-
tor activity, as measured in the open field (OF) appara-
tus. Moreover, the antidepressant-like activity of EMD
386088 was observed in an olfactory bulbectomy (OB)
model of depression following chronic administration to
rats (Jastrzębska-Więsek et al. 2015).
The present series of experiments was aimed at evaluating
the mechanism of the antidepressant-like effect produced by
EMD 386088 and observed in the modified FST in rats After
the end of the FST, we carried out neurochemical ex vivo
studies in rats’ brain structures (hippocampus, NAc, and stri-
atum) to correlate the observed antidepressant effect of EMD
386088 with the levels of monoamines and their metabolites,
the rate of monoamine metabolism, and indices of neural ac-
tivity. Moreover, EMD 386088 was also tested in a functional
in vitro assay of its potency to blockade DAT, the study con-
ducted by Cerep company.
In the second part of experiments, the influence of D1- and
D2-like receptor subfamily antagonists (SCH 23390 and
sulpiride, respectively), on the antiimmobility effect induced
by EMD 386088 has been examined in the FST. The dosage
and time schedules of EMD 386088 were based on the results
of our earlier studies (Jastrzębska-Więsek et al. 2015), where-
as the antagonists of D1 and D2 receptor subfamilies were used
at doses effective in blocking the effects induced by agonists
of respective receptors (Rogóz and Skuza 2006; Hirano et al.
2007; Stuchlik et al. 2007).
Materials and methods
Animals
The experiments were performed on male Wistar rats
(250–300 g) purchased from Charles River Laboratories
(Germany). The animals were housed for a period of
6 days in polycarbonate Makrolon type 3 cages (dimen-
sions 26.5 × 15 × 42 cm) in an environmentally controlled
room (ambient temperature 21 ± 2 °C; relative humidity
50–60 %; 12:12 light/dark cycle, lights on at 8:00), in
groups of four rats. Standard laboratory food (LSM-B)
and filtered water were freely available. Animals were
assigned randomly to treatment groups. All the experi-
ments were performed by two observers unaware of the
treatment applied between 9:00 and 14:00 on separate
groups of animals. Procedures involving animals and their
care were conducted in accordance with the current
European Community and Polish legislation on animal
experimentation. Additionally, all efforts were made to
minimize animal suffering and to use only the number of
animals necessary to produce reliable scientific data. The
experimental protocols and procedures described in this
manuscript were approved by the IV Local Ethics
Commission in Warsaw (no 40/2008) and complied with
the European Communities Council Directive of 24
November 1986 (86/609/EEC) and were in accordance
with the 1996 NIH Guide for the Care and Use of
Laboratory Animals.
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Drugs
The following drugs were used: 5-chloro-2-methyl-3-(1,2,3,6-
tetrahydro-4-pyridinyl)-1H-indole hydrochloride (EMD
386088) was synthesized by Adamed (Pienków, Poland),
SCH 23390 hydrochloride ((R)-(+)-7-chloro-8-hydroxy-3-
methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hy-
drochloride, Tocris, UK). All drugs were dissolved in distilled
water immediately before administration in a volume of 2 ml/
kg. All the compounds were administered intraperitoneally
(i.p.). EMD 386088 was given 30 min before the test, while
the remaining compounds were injected 60 min before.
Control animals received vehicle (0.9 % sodium chloride,
NaCl) according to the same schedule.
FST in rats
The experiment was carried out according to the modified, by
Detke et al. (1995), method of Porsolt et al. (1978). On the first
day of an experiment, the animals were gently individually
placed in Plexiglas cylinders (40 cm high, 18 cm in diameter)
containing 30 cm of water maintained at 23–25 °C for 15 min.
On removal from water, the rats were placed for 30 min in a
Plexiglas box under 60-W bulb to dry. On the following day
(24 h later), the rats were replaced in the cylinder and the total
duration of immobility, swimming, and climbing was record-
ed during the whole 5-min test period. The swimming behav-
ior entailed active swimming motions, e.g., moving horizon-
tally around in the cylinder. Climbing activity consisted of
upward directed movements of the forepaws along the side
of the swim chamber, and immobility was assigned when no
additional activity was observed other than that necessary to
keep the rat’s head above the water (Detke et al. 1995). Fresh
water was used for each animal.
Biochemical studies
Ex vivo: monoamine metabolism in rat brain structures
After the end of the FST, the rats were killed by decapitation
and the brain was rapidly removed and dissected on different
brain structures (hippocampus, nucleus accumbens, and
striatum) on an ice-cold glass plate. The structures were fro-
zen on solid CO2 (−70 °C) until used for biochemical assays.
DA and i ts metabol i tes , the int raneuronal , 3 ,4-
dihydroxyphenylacetic acid (DOPAC); the extraneuronal, 3-
methoxytyramine (3-MT) and the final metabolite,
homovanillic acid (HVA); NA and its main extraneuronal
brain metabolite, normetanephrine (NM); and 5-HT and its
intraneuronal metabolite 5-hydroxyindolacetic acid (5-
HIAA) were assayed by means of high-performance liquid
chromatography (HPLC) with electrochemical detection
(ED). The tissue samples were weighted and homogenized
in ice-cold 0.1 M trichloroacetic acid containing 0.05 mM
ascorbic acid. After centrifugation (10,000×g, 5 min), the su-
pernatants were filtered through RC58 0.2-μm cellulose mem-
branes (Bioanalytical Systems, West Lafayette, IN, USA).
The chromatograph HP 1050 (Hewlett-Packard, Golden,
CO, USA) was equipped with Hypersil columns BDS-C18
(4 × 100 mm, 3 μm). The mobile phase consisted of 0.05 M
citrate-phosphate buffer, pH 3.5; 0.1 mM EDTA; 1 mM sodi-
um octyl sulfonate; and 3.5 % methanol. The flow rate was
maintained at 1 ml/min. DA, NA, and 5-HT and their metab-
olites were quantified by peak area comparisons with stan-
dards run on the day of analysis (ChemStation, Hewlett-
Packard software computer program).
In vitro: affinity for dopamine transporter (DAT)
EMD 386088 was tested in functional in vitro (human recom-
binant CHO cells) assay of its potency to block dopamine
transporter (DAT) conducted by Cerep (Le Bois l’Eveque,
8600 Celle L’Evescault, France). The standard Cerep assay
protocol was used (see for details: http://www.cerep.fr/cerep/
users/pages/ProductsServices/BindingPlatform.asp, and
http://www.cerep.fr/cerep/users/pages/catalog/Affiche_
CondExp_Test.asp?test=52).
OF test in rats
The experiment was performed in a darkened room using
Motor Monitor System (Campden Instruments, Ltd., UK)
consisted of two SmartFrame Open Field stations
(40 × 40 × 38 cm) with 16 × 16 beams, located in sound-
attenuating chambers and connected to a PC software by con-
trol chassis. Individual vehicle- or drug-injected animals were
gently placed in the center of the station. An automatedMotor
Monitor System recorded ambulation (in X and Y axis), the
number of rearing and peeping episodes, and total distance
covered by a rat for 5 min.
Statistical analysis
The data of behavioral studies were evaluated by an analysis
of variance: one-way ANOVA (when one drug was given) or
two-way ANOVA (when two drugs were used) followed by
Duncan’s post hoc test; p < 0.05 was considered significant.
The results of the biochemical studies were analyzed using
one-way ANOVA followed by Duncan’s post hoc test when
appropriate. The data were considered statistically significant
when p < 0.05.
The total catabolism rate for DA was assessed from the
ratio of the final DA metabolite concentration; HVA to DA
concentration and expressed as the catabolic rate index
[HVA] / [DA] × 100; the rate of DA monoamine oxidase
(MAO)-dependent oxidation as the ratio [DOPAC] /
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[DA] × 100; the rate of DA COMT-dependent O-methylation
as the ratio [3-MT] / [DA] × 100; the factor of DA reuptake
inhibition as the ratio [3-MT] / [DOPAC] × 100. Analogously,
the rate of NA metabolism was expressed as the ratio [NM] /
[NA] × 100 and 5-HT as the ratio [5-HIAA] / [5-HT] × 100.
The indices were calculated using concentrations from indi-
vidual tissue samples (Antkiewicz-Michaluk et al. 2001).
Results
Antidepressant-like activity of EMD 386088 after single
i.p. administration in the modified FST in rats
EMD 386088 administered i.p. only at a dose of 5 mg/kg
significantly decreased the immobility (ANOVA: F(2,
19) = 5.906; p < 0.01) and increased the swimming behaviors
(ANOVA: F(2, 19) = 7.031; p < 0.01) of rats in the FST. There
was no significant drug effect on the duration of climbing
(ANOVA: F(2, 19) = 0.034; not significant, NS) (Fig 1).
Biochemical studies
The ex vivo studies were conducted immediately after the end
of the FST. The rats were killed by decapitation and the se-
lected tissues were collected.
The effect of EMD 386088 on the concentration of DA and its
metabolites and on the rate of DA metabolism in rat brain
structures
The one-way ANOVA showed no significant effect of EMD
386088 (2.5 and 5 mg/kg) on DA and its extraneuronal me-
tabolite 3-MT concentrations in the brain structures (Tables 1
and 2). At the same time, the statistical analysis revealed a
significant effect of EMD 386088 on the level of the DA
metabolites: an intraneuronal DOPAC and final HVA in
NAc and striatum. The Duncan post-hoc test indicated that
EMD 386088 (2.5 and 5.0 mg/kg) significantly decreased
(from 20 to 30 %; p < 0.05) DOPAC and HVA concentration
in a dose-related manner (Table 1).
The one-way ANOVA showed a significant effect of EMD
386088 administration on the rate of final DA metabolism,
[HVA] / [DA] in the hippocampus (F(2, 20) = 4.53,
p < 0.05), NAc (F(2, 21) = 14.54, p < 0.0001), and striatum
(F(2, 21) = 4.35, p < 0.05). At the same time, the statistical
analysis demonstrated a dose-dependent significant decrease
in the rate of DA oxidation [DOPAC] / [DA] and no effect on
the rate of DA methylation [3-MT]/[DA] after EMD 386088
(2.5 and 5 mg/kg) administration in all the investigated struc-
tures. The factor of dopamine reuptake inhibition expressed as
the ratio [3-MT]/[DOPAC] was increased in the all investigat-
ed brain structures (Table 2).
The effect of EMD 386088 on the concentration of 5-HT
and its metabolite and on the rate of 5-HT metabolism in rat
brain structures
The one-way ANOVA showed no significant effect of EMD
386088 (2.5 and 5 mg/kg) administration on 5-HT and its
intraneuronal metabolite 5-HIAA concentrations in all the in-
vestigated brain structures (Table 3).
The effect of EMD 386088 on the concentration of NA and its
extraneuronal metabolite, normetanephrine, and on the rate
of NA metabolism in rat brain structures
The one-way ANOVA demonstrated no significant effect of
EMD 386088 (2.5 and 5 mg/kg) administration on NA and its
metabolite NM as well as on the rate of NAmetabolism in the
hippocampus and NAc (Table 4).
The affinity of EMD 386088 for DAT
EMD 386088 showed significant affinity for human DAT
(Ki = 41 nM). In the same experiment, Ki for the referenced
compound 1-[1-(2-Benzo [b]thienyl)cyclohexyl)]piperidine
(BTCP) was 6.5 nM.
The influence of SCH 23390 and sulpiride
on the antidepressant-like effect induced by EMD 386088
in the FST in rats
EMD 386088 administered i.p. at a dose of 5 mg/kg showed
antidepressant-like activity in FST, significantly decreasing
the immobility and increasing the swimming behaviors of rats
in this test. SCH 23390 (0.063 mg/kg) and sulpiride
(10 mg/kg), administered alone did not change the behavioral
parameters observed in FST (Fig. 2).
Fig. 1 Antidepressant-like properties of EMD 386088 in the modified
FST in rats. EMD 386088 was injected i.p. 30 min. Values represent the
mean ± SEM during the 5-min test session; **p < 0.01, vs. vehicle group
(one-way ANOVA is followed by the Duncan’s post hoc test); N = 7–8
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SCH 23390 (0.063 mg/kg) diminished an antidepressant-
like effect of EMD 386088 (5 mg/kg) (Fig. 2a). The two-way
ANOVA demonstrated a significant interaction of this
cotreatment on the immobility time (F(1, 26) = 10.096,
p < 0.01) and in the swimming behavior (F(1, 26) = 13.344,
p < 0.01), but no significant interaction for climbing behavior
was observed (F(1, 26) = 2.897, ns) (Fig.2a).
Sulpiride (10 mg/kg) given concomitantly with EMD
386088 (5 mg/kg) reversed the antiimmobility action evoked
by EMD 386088 in the statistically significant manner (two-
way ANOVA: F(1, 27) = 10.835, p < 0.01) as well as signif-
icantly decreased swimming behavior (two-way ANOVA:
F(1, 27) = 12.803, p < 0.01) (Fig. 1b). The two-way
ANOVA demonstrated no significant interaction for climbing
behavior (F(1, 27) = 0.442, ns; Fig.2b).
OF test in rats
EMD 386088 (2.5 and 5 mg/kg) administered alone
(Jastrzębska-Więsek et al. 2015) or in combination with
SCH 23390 (0.063 mg/kg) or sulpiride (10 mg/kg) did not
change the exploratory activity of rats (Table 5). SCH 23390
(0.063 mg/kg) given alone significantly decreased ambulation
of rats or total distance and Yambulation of rats, respectively.
However, two-way ANOVA showed no significant interac-
tion in all observed parameters of exploratory activity in those
conducted experiments (Table 5).
Discussion
Our results indicate for the first time that the dopaminergic
system is involved in the antidepressant-like activity of a 5-
HT6 receptor partial agonist EMD 386088, which is observed
in the modified FST in rats. In this study, we investigated the
effects of i.p. treatment of EMD 386088 on behavioral (FST,
OF test) and neurochemical parameters, and then we studied
the effect of blockade of D1- and D2-like receptor subfamilies
on the antidepressant-like properties of EMD 386088 in FST.
The obtained behavioral results are in accordance with the
biochemical ex vivo and radioligand in vitro investigations,
which are presented in this paper.
In line with our earlier study (Jastrzębska-Więsek et al.
2015), the administration of EMD 386088 produced an
antidepressant-like effect detected in the modified FST in rats.
Specifically, EMD 386088, given at a dose of 5 mg/kg, exerts
antidepressant-like properties as revealed by shortening of im-
mobility and increasing in swimming behaviors (Fig 1). The
Table 1 The effect of EMD 386088 on the concentration of DA and its metabolites in rat brain structures
Treatment (mg/kg) DA
(ng/g t)
DOPAC
(ng/g t)
3-MT
(ng/g t)
HVA
(ng/g t)
Hippocampus
Vehicle 0 42 ± 10 9 ± 1.9 1.0 ± 0.5 14 ± 1.7
EMD 386088 2.5 58 ± 4 5 ± 0.6 1.5 ± 0.4 12 ± 0.9
5 51 ± 4 5 ± 0.5 1.3 ± 0.6 13 ± 0.7
F(2, 20) = 1.25
NS
F(2, 20) = 2.9
NS
F(2, 21) = 0.21
NS
F(2, 21) = 0.47
NS
Nucleus accumbens
Vehicle 0 9756 ± 777 2066 ± 181 139 ± 18 1195 ± 102
EMD386088 2.5 9586 ± 389 1722 ± 73 169 ± 20 849 ± 41**
5 10,017 ± 505 1614 ± 79* 143 ± 6 843 ± 39**
F(2, 21) = 0.14
NS
F(2, 21) = 3.76
p < 0.05
F(2, 21) = 1.02
NS
F(2, 21) = 8.82
p < 0.01
Striatum
Vehicle 0 11,386 ± 325 1773 ± 61 336 ± 7 1487 ± 111
EMD386088 2.5 11,305 ± 298 1589 ± 52* 329 ± 11 1228 ± 7 9*
5 11,253 ± 327 1430 ± 47** 332 ± 12 1180 ± 66*
F(2, 21) = 0.33
NS
F(2, 21) = 8.76
p < 0.01
F(2, 21) = 1.53
NS
F(2, 21) = 5.06
p < 0.05
EMD386088 was injected i.p. in a dose of 2.5 and 5 mg/kg; control group was treated i.p. with saline. The rats were decapitated about 30 min after drug
injection. The results are expressed as the mean ± SEM (N = 8). The indices were calculated using concentrations from individual tissue samples. The
concentration of dopamine and its metabolites were measured in ng/g tissue. The data were analyzed by means of one-way ANOVA, followed by
Duncan’s post hoc test
NS not significant
Statistical significance: *p < 0.05, **p < 0.01 vs. respective control group
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effect of EMD 386088was directly blocked by the selective 5-
HT6 receptor antagonist SB-271,046 administered in an inac-
tive dose (Jastrzębska-Więsek et al. 2015). Furthermore, its
antidepressant-like effect, mediated by stimulation of 5-HT6
receptors, seems to be specific, because EMD 386088 did not
affect rats’ total distance measured in the OF apparatus. The
shortening of immobility time, induced by antidepressant
drugs in FST, depends on the enhancement of the central 5-
HTand catecholamine transmission (Porsolt et al. 1977, 1978;
Borsini and Meli 1988; Borsini 1995).
To investigate the impact of EMD 386088 on the rate of
monoamine (DA, NA, and 5-HT) metabolism, the biochemi-
cal ex vivo assays were conducted. For presentation neuro-
chemical results, we selected three brain structures connected
with monoaminergic function and with high 5-HT6 receptor
mRNA expression, i.e., striatum, NAc, and hippocampus.
Moreover, literature data has shown that modifications of
monoamine transmission in these brain structures play an im-
portant role in the pathophysiology of depression. Therefore,
NAc plays an important role in depression symptomatology,
especially reducing motivation and causing anhedonia
(Francis et al. 2015) as well as striatal dopamine modulates
emotional and motor symptoms of depression (Rogers et al.
1998; Amsterdam and Newberg 2007). Neurochemical data
showed that an observed antidepressant-like effect of EMD
386088 may be connected with the activation of monoamin-
ergic, especially dopaminergic, system in rats’ brain. EMD
386088 given at the investigated doses (2.5 and 5 mg/kg)
changed the DA metabolism and activity of the dopaminergic
system in all investigated brain structures, i.e., hippocampus,
NAc, and striatum. The administration of EMD 386088 did
not change DA level and its extraneuronal metabolite 3-MT,
but it significantly decreased the level of DA metabolites: an
intraneuronal DOPAC and final HVA in the brain structures,
except the hippocampus.Moreover, EMD 386088 significant-
ly decreased the rate of final DA metabolism ([HVA]/[DA])
and the rate of DA intracellular oxidation ([DOPAC]/[DA]) of
metabolic pathway. As it is well known, the intracellular DA
oxidation by MAO is closely connected with the formation of
free radicals leading to oxidative stress. Now there are many
studies showing that depression is characterized by a signifi-
cantly decreased antioxidant status as evidenced by lowered
tryptophan, tyrosine, vitamin E, zinc, and reduced glutathione,
which are all antioxidants (Maes 2008; Maes et al. 2011). In
that light, antioxidant activity of EMD 386088 demonstrated
by decreasing the rate of DA intracellular oxidation
Table 2 The effect of EMD 386088 administration on rate of DA metabolism in rat brain structures
Treatment (mg/kg) [DOPAC]/
[DA]
[3-MT]/
[DA]
[3-MT]/
[DOPAC]
[HVA]/
[DA]
Hippocampus
Vehicle 0 28 ± 5.1 1.7 ± 0.6 8 ± 2.8 56 ± 14.2
EMD386088 2.5 9 ± 1.2** 2.7 ± 0.9 27 ± 7.4* 22 ± 1.6*
5 10 ± 1.0** 2.0 ± 1.3 23 ± 16.3 27 ± 2.1*
F(2, 20) = 11.03
p < 0.001
F(2, 20) = 0.28
NS
F(2, 20) = 4.11
p < 0.05
F(2, 20) = 4.53
p < 0.01
Nucleus accumbens
Vehicle 0 21 ± 0.7 1.4 ± 0.1 7 ± 0.3 12 ± 0.8
EMD386088 2.5 18 ± 0.4** 1.7 ± 0.2 10 ± 0.9.** 9 ± 0.4**
5 16 ± 0.7** 1.4 ± 0.1 9 ± 0.1* 8 ± 0.5**
F(2,21) = 18.3
p < 0.0001
F(2, 21) = 2.52
NS
F(2, 21) = 6.81
p < 0.01
F(2, 21) = 14.54
p < 0.0001
Striatum
Vehicle 0 15 ± 0.3 2.9 ± 0.1 19 ± 0.6 13 ± 0.7
EMD386088 2.5 14 ± 0.4* 3.3 ± 0.1 23 ± 0.5** 10 ± 0.7*
5 13 ± 0.4** 2.9 ± 0.1 23 ± 0.7** 10 ± 0.6*
F(2, 21) = 13.99
p < 0.0001
F(2, 21) = 3.88
p < 0.05
F(2, 21) = 13.68
p < 0.0001
F(2, 21) = 4.35
p < 0.05
EMD386088 was injected i.p. in a dose of 2.5 and 5 mg/kg; control group was treated i.p. with saline. The rats were decapitated about 30 min after drug
injection. The results are expressed as the mean ± SEM (N = 8). The rate of DA total metabolism was expressed as the ratio [HVA] / [DA] × 100; the rate
of DA MAO-dependent oxidation as the ratio: [DOPAC] / [DA] × 100; the rate of the inhibition of dopamine reuptake as the ratio: [3-MT] /
[DOPAC] × 100; and the rate of COMT-dependent O-methylation as the ratio: [3-MT] / [DA] × 100. The indices were calculated using concentrations
from individual tissue samples. The data were analyzed by means of one-way ANOVA, followed by Duncan’s post hoc test
NS not significant
Statistical significance: *p < 0.05, **p < 0.01 vs. respective control group
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Table 3 The effect of EMD
386088 administration on 5-HT
and its metabolite concentration
and 5-HT metabolism in rat brain
structures
Treatment (mg/kg) 5-HT
(ng/g t)
5-HIAA
(ng/g t)
[5-HIAA]/
[5-HT]
Hippocampus
Vehicle 0 275 ± 11 168 ± 15 61 ± 5
EMD386088 2.5 294 ± 11 185 ± 9 63 ± 2
5 288 ± 11 173 ± 15 59 ± 4
F(2, 21) = 0.79
NS
F(2, 21) = 0.44
NS
F(2, 21) = 0.22
NS
Nucleus accumbens
Vehicle 0 481 ± 42 324 ± 21 69 ± 5
EMD386088 2.5 551 ± 16 354 ± 14 64 ± 3
5 435 ± 31 298 ± 20 69 ± 3
F(2, 21) = 3.44
NS
F(2, 21) = 2.17
NS
F(2, 21) = 0.41
NS
Striatum
Vehicle 0 369 ± 19 358 ± 22 97 ± 4
EMD386088 2.5 381 ± 13 392 ± 16 103 ± 3
5 346 ± 18 352 ± 18 103 ± 6
F(2, 21) = 1.14
NS
F(2, 21) = 1.26
NS
F(2, 21) = 0.54
NS
EMD386088 was injected i.p. in a dose of 2.5 and 5 mg/kg; control group was treated i.p. with saline. The rats
were decapitated about 30 min after drug injection. The results are expressed as the mean ± SEM (N = 8). The
concentration of serotonin (5-HT) and its metabolite, 5-hydroxyindolacetic acid (5-HIAA), was expressed as ng/g
tissue. The rate of 5-HT metabolism was expressed as the ratio [5-HIAA] / [5-HT] × 100. The indices were
calculated using concentrations from individual tissue samples. The data were analyzed by means of one-way
ANOVA, followed by Duncan’s post hoc test
NS not significant
Table 4 The effect of EMD
386088 administration onNA and
its metabolite concentration and
NA metabolism in rat brain
structures
Treatment (mg/kg) NA
(ng/g t)
NM
(ng/g t)
[NM]/
[NA]
Hippocampus
Vehicle 0 312 ± 15 14 ± 1.3 5 ± 0.4
EMD386088 2.5 324 ± 16 16 ± 0.9 5 ± 0.3
5 300 ± 22 15 ± 1.6 5 ± 0.4
F(2, 21) = 0.46
NS
F(2, 21) = 0.45
NS
F(2, 21) = 0.31
NS
Nucleus accumbens
Vehicle 0 443 ± 48 15 ± 1.0.8 4 ± 0.1
EMD386088 2.5 443 ± 40 14 ± 0.8 4 ± 0.2
5 445 ± 47 13 ± 0.8 5 ± 0.1
F(2, 21) = 0.01
NS
F(2, 21) = 0.0
NS
F(2, 21) = 0.99
NS
EMD386088 was injected i.p. in a dose of 2.5 and 5 mg/kg; control group was treated i.p. with saline. The rats
were decapitated about 30 min after drug injection. The results are expressed as the mean ± SEM (N = 8). The
concentration of NA and its metabolite, normetanephrine (NM), was expressed as ng/g tissue. The rate of NA
metabolism was expressed as the ratio of the extraneuronal metabolite NM to NA: [NM] / [NA] × 100. The
indices were calculated using concentrations from individual tissue samples. The data were analyzed by means of
one-way ANOVA, followed by Duncan’s post hoc test
NS not significant
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([DOPAC]/[DA]) in all investigated brain structures correlates
well with antidepressant-like activity of EMD 386088 in FST
in rats. It may be concluded that intracellular inhibition of DA
MAO-dependent oxidation would be one of the molecular
mechanisms responsible for its antidepressant-like activity
(Maes et al. 2011; Antkiewicz-Michaluk et al. 2014;
Możdżeń et al. 2014). At the same time, the increase in a
factor pointing to the DA uptake inhibition properties ([3-
MT]/[DOPAC]) was observed. Such biochemical effects
may suggest the stimulation of DA receptors through DA
reuptake inhibition which occurred after EMD 386088 treat-
ment. In fact, the affinity of EMD 386088 for DAT was also
investigated. This compound binds to this transporter in
nanomolar ratio of concentration, and this activity differs
EMD 386088 from another 5-HT6 receptor agonist ST 1936
(Borsini et al. 2008). The DAT is the target for drugs used to
treat depression (i.e., nomifensine), attention deficit hyperac-
tivity disorder (ADHD) (i.e., methylphenidate), or addiction
(bupropion) as well as for psychostimulants such as cocaine
and amphetamine. Moreover, there was observed in DAT
knockout mice frontal cortex significant decreasing of brain-
derived neurotrophin factor (BDNF) mRNA levels (Haenisch
and Bönisch 2011). The biochemical studies followed by
Valentini et al. (2011) showed that systemic administration
of ST 1936 dose-dependently increased dialyzate DA and
NA in the shell of the NAc and mPFX. The mechanism of
Fig. 2 The influence of SCH 23390 (a) and sulpiride (b) on the
antidepressant-like effect induced by EMD 386088 in the FST in rats.
EMD 386088 was administered i.p. 30 min before the test, while SCH
23390 and sulpiride were given 60 min before. The animals were
observed for 5 min. The results represent the mean ± SEM of 6–8 rats.
The data were statistically evaluated by two-way ANOVA followed by
Duncan’s post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 vs. respective
vehicle group, ##p < 0.01, ###p < 0.001 vs. respective EMD 386088 group
Table 5 Effect of EMD 386088, SCH 23390, and sulpiride given alone or in combination on the rat locomotor activity measured in the OF test
Treatment Dose (mg/kg) Exploratory activity
Total distance (cm) Rearings Ambulation X Ambulation Y
Vehicle + vehicle 0 + 0 2477 ± 164 65 ± 9 224 ± 28 236 ± 22
Vehicle + SCH 23390 0 + 0.063 1898 ± 196 55 ± 8 125 ± 13* 136 ± 13*
Vehicle + EMD 386088 0 + 5 3354 ± 358 86 ± 10 308 ± 29 330 ± 28*
SCH 23390 + EMD 386088 0.063 + 5 2227 ± 190 62 ± 5 172 ± 25 188 ± 22
F(1, 23) = 1.4296; NS F(1, 23) = 0.6977; NS F(1, 23) = 0.5631; NS F(1, 23) = 0.9170; NS
Vehicle + vehicle 0 + 0 2693 ± 222 84 ± 7 234 ± 26 237 ± 23
Vehicle + sulpiride 0 + 10 3324 ± 332 66 ± 9 352 ± 13 325 ± 35
Vehicle + EMD 386088 0 + 5 3354 ± 358 86 ± 10 308 ± 29 330 ± 28
Sulpiride + EMD 386088 5 + 10 3106 ± 358 81 ± 8 345 ± 32 357 ± 37
F(1, 20) = 2.4700; NS F(1, 20) = 0.5780; NS F(1, 20) = 1.4950; NS F(1, 20) = 0.9490; NS
EMD 386088 was injected i.p. 30min, while the remaining compounds were injected 60min before. Values represent the mean ± SEM during the 5-min
test session compared to the respective vehicle + vehicle group (two-way ANOVA is followed by the Duncan’s post hoc test) (N = 6)
NS not significant
*p < 0.05
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these effects was unlikely to be due to blockade of the DAT
and of the NET, as ST 1936 did not bind to these transporters
(Borsini et al. 2008; Valentini et al. 2011). Furthermore, this
compound, in some behavioral tests, was shown to induce
conditioned place preference and conditioned saccharin aver-
sion and to be self-administered by rats, which indicate the
DA-stimulant properties of ST 1936 in the NAc shell
(Valentini et al. 2011). The study on effects of ST 1936 on
electrical activity of putative mesencephalic dopaminergic
neurons in the rat brain showed that it can either increase or
decrease the basal firing rates of these DA-containing neurons
in the ventral tegmental area and did not affect the basal firing
activity of dopaminergic neurons in the substantia nigra pars
compacta after systemic administration (Borsini et al. 2015).
In case of the decrease in the basal firing rate, the authors
suggested that the systemic administration of ST 1936 might
have acted on different sites through the GABA neurons that
control these DA neurons (Borsini et al. 2015). Previous stud-
ies have also shown that agonists of 5-HT1A receptors are able
to increase extracellular DA level in the PFX (Arborelius et al.
1993; Tanda et al. 1994). However, these agonists also de-
crease extracellular 5-HT through the activation of
somatodendritic 5-HT1A autoreceptors. In our investigations,
EMD 386088, given in an active antidepressant-like dose
(5 mg/kg), does not affect 5-HT and its intraneuronal metab-
olite (5-HIAA) concentrations in all the investigated brain
structures. Moreover, its affinity for 5-HT1A receptors is about
44-fold weaker (Ki = 320 nM) than that for 5-HT6 receptors
(EC50 = 1 nM) (Mattsson et al. 2005). In this paper, we also
have demonstrated that there was no significant effect of EMD
386088 administration on NA and its metabolite (NM) and on
the rate of NA metabolism in the selected brain structures.
Recently, in a microdialysis study, Valentini et al. (2011) dem-
onstrated that systemic administration of ST 1936 dose-
dependently increased dialyzate NA in the shell of NAc and
in the mPFX, and to a lesser extent, in the NAc core. On the
contrary, in the microdialysis study, the partial 5-HT6 receptor
agonist WAY-181,187 following systemic acute sc adminis-
tration modestly yet significantly decreased cortical 5-HT and
DA levels and decreased striatal DA level (Schechter et al.
2008). The reported differences in effects evoked by 5-HT6
receptor agonists and partial agonists may be caused by vari-
ous factors, i.e., their selectivity for 5-HT6 receptor over other
receptors, the investigated brain structures, and the method
used, i.e., microdialysis study vs. ex vivo study (WAY
181187 and ST 1936 vs. EMD 386088, respectively). The
results obtained presently demonstrate that dopaminergic sys-
tem, but not the noradrenergic one, plays an important role in
the antiimmobility activity of EMD 386088, since this effect
was abolished by the preferential D1- and D2-like receptor
subfamily antagonists SCH 23390 and sulpiride, respectively.
Both antagonists per se did not show any antidepressant-like
effects. It is noteworthy that neither SCH 23390 nor sulpiride
at the doses used, administered jointly with EMD 386088,
modified the distance traveled by rats and measured in OF
test; hence, their antagonism toward EMD 386088 in the
FST cannot be attributed to a competing behavior, such as
locomotor activity.
The results present in this paper seem to suggest a different
indirect mechanism of antidepressant-like activity of a 5-HT6
receptor partial agonist EMD 386088 than that established for
selective 5-HT6 antagonists. For example, SB 399885, the
selective 5-HT6 receptor antagonist, exerts antidepressant-
like properties by shortening immobility time in the FST in
rats. Its activity in this model was connected with activation of
D1- and D2-like receptors and α2-adrenoceptors, additionally
not requiring any integrity of serotonergic neurons
(Wesołowska 2007). SB 271046, another 5-HT6 receptor an-
tagonist, significantly increased cortical and hippocampal ex-
tracellular concentrations of DA, NA (Lacroix et al. 2004),
and acetylcholine in freely moving rats (Loiseau et al. 2008).
Also, we cannot exclude the role of other neurotransmitters
in the antidepressant-like activity of EMD 386088 yet, i.e.,
acetylcholine. The clinical data suggest that hypercholinergic
neurotransmission is associated with depressed mood stated
and may be mediated through excessive neuronal nicotinic
activation (Shytle et al. 2002). Moreover, in the preclinical
investigations, it was shown that nicotinic receptor antagonists
potentiate the antidepressant-like effects of imipramine and
citalopram (Popik et al. 2003) and decrease the time of immo-
bility in the forced swim and tail-suspension tests in mice
(Borsini and Meli 1988; Cryan et al. 2005). Up to now, there
is no in vivo or in vitro data available showing an effect of
EMD 386088 on cholinergic system activity and acetylcho-
line ratio in brain structures, but such activity of EMD 386088
cannot be excluded, especially in view of the results demon-
strating that 5-HT6 receptor antagonists increase extracellular
acetylcholine level (Hirst et al. 2003, 2006) so probably 5-HT6
receptor agonists should it decreased, but till now, no data are
available. On the contrary, it was also observed that both stim-
ulation (by EMD 386088 and E-6801) and blockade (SB
271046) of 5-HT6 receptors exert procognitive action ob-
served by reversing scopolamine-disrupted consolidation of
passive avoidance task (Woods et al. 2012).
Conclusions
The results described in this paper indicate that dopaminergic
system is involved in the antidepressant-like activity of EMD
386088 via D1- and D2-like receptors and DAT. The intriguing
neurochemical and receptor profile of EMD 386088, a partial
5-HT6 receptor agonist, supports the rationale for investigat-
ing its potential therapeutic benefits in the clinical manage-
ment of depression and other disorders connected with
hypofunction of the dopaminergic system.
Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:839–849 847
Acknowledgments The study was financially supported by Adamed
Ltd., NCBiR, Warsaw, Poland (project no. KB/88/12655/ITT1-C/U/08)
and funds for Statutory Activity of Jagiellonian University Medical
College, Cracow, Poland (K/ZDS/004121) and was supported by statu-
tory funds of the Neurochemistry Department, Institute of Pharmacology
Polish Academy of Sciences, Krakow, Poland.
Compliance with ethical standards
Ethical approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed. All the
experimental procedures performed in studies involving animals were
approved by the IV Local Ethics Commission in Warsaw (no 40/2008)
and were in accordance with the 1996 NIH Guide for the Care and Use of
Laboratory Animals.
Conflict of interest The authors declare that they have no conflict of
interest. Marcin Kołaczkowski is an employee of Adamed Ltd.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Amsterdam JD, Newberg AB (2007) A preliminary study of dopamine
transporter binding in bipolar and unipolar depressed patients and
healthy controls. Neuropsychobiology 55:167–170. doi:10.1159/
000106476
Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, et al. (2001) Different
action on dopamine catabolic pathways of two endogenous 1,2,3,4-
tetrahydroisoquinolines with similar antidopaminergic properties. J
Neurochem 78:100–108
Antkiewicz-Michaluk L, Wasik A, Mozdzeń E, et al. (2014)
Antidepressant-like effect of tetrahydroisoquinoline amines in the
animal model of depressive disorder induced by repeated adminis-
tration of a low dose of reserpine: behavioral and neurochemical
studies in the rat. Neurotox Res 26:85–98. doi:10.1007/s12640-
013-9454-8
Arborelius L, Chergui K, Murase S, et al. (1993) The 5-HT1A receptor
selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially
affect the activity of midbrain dopamine neurons. Naunyn
Schmiedeberg's Arch Pharmacol 347:353–362
Borsini F (1995) Role of the serotonergic system in the forced swimming
test. Neurosci Biobehav Rev 19:377–395
Borsini F, Meli A (1988) Is the forced swimming test a suitable model for
revealing antidepressant activity? Psychopharmacology 94:147–
160
Borsini F, Stasi M, Minetti P, et al. (2008) Effect of ST 1936, a 5-HT6
ligand, on rodent adenylate cyclase and forced swimming test. Int J
Neuropsychopharmacol 11:123–124
Borsini F, Bordi F, Poggi A, Di Matteo V (2015) Effects of ST1936, a
selective serotonin-6 agonist, on electrical activity of putative mes-
encephalic dopaminergic neurons in the rat brain. doi:10.1177/
0269881115573804
Carr GV, Schechter LE, Lucki I (2011) Antidepressant and anxiolytic
effects of select ive 5-HT6 receptor agonists in rats.
Psychopharmacology 213:499–507. doi:10.1007/s00213-010-
1798-7
Cryan JF, Valentino RJ, Lucki I (2005) Assessing substrates underlying
the behavioral effects of antidepressants using the modified rat
forced swimming test. Neurosci Biobehav Rev 29:547–569. doi:
10.1016/j.neubiorev.2005.03.008
Dawson LA, Nguyen HQ, Li P (2001) The 5-HT6 receptor antagonist
SB-271046 selectively enhances excitatory neurotransmission in the
rat frontal cortex and hippocampus. Neuropsychopharmacology 25:
662–668. doi:10.1016/S0893-133X(01)00265-2
Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced
swimming test differentially produced by serotonergic and norad-
renergic antidepressants. Psychopharmacology 121:66–72
Fone KCF (2008) An update on the role of the 5-hydroxytryptamine6
receptor in cognitive function. Neuropharmacology 55:1015–1022.
doi:10.1016/j.neuropharm.2008.06.061
Francis TC, Chandra R, Friend DM, et al. (2015) Priority communication
nucleus accumbens medium spiny neuron subtypes mediate
depression-related outcomes to social defeat stress. Biol Psychiatry
77:212–222. doi:10.1016/j.biopsych.2014.07.021
Gérard C, el Mestikawy S, Lebrand C, et al. (1996) Quantitative RT-PCR
distribution of serotonin 5-HT6 receptor mRNA in the central ner-
vous system of control or 5,7-dihydroxytryptamine-treated rats.
Synapse 23:164–173. doi:10.1002/(SICI)1098-2396(199607)
23:3&lt;164::AID-SYN5&gt;3.0.CO;2-6
Gérard C, Martres MP, Lefèvre K, et al. (1997) Immune-localization of
serotonin 5-HT6 receptor-like material in the rat central nervous
system. Brain Res 746:207–219. doi:10.1016/S0006-8993(96)
01224-3
Haenisch B, Bönisch H (2011) Depression and antidepressants: insights
from knockout of dopamine, serotonin or noradrenaline re-uptake
transporters. Pharmacol Ther 129:352–368. doi:10.1016/j.
pharmthera.2010.12.002
Heal DJ, Smith SL, Fisas A, et al. (2008) Selective 5-HT6 receptor li-
gands: progress in the development of a novel pharmacological
approach to the treatment of obesity and related metabolic disorders.
Pharmacol Ther 117:207–231. doi:10.1016/j.pharmthera.2007.08.
006
Hirano S, Miyata S, Onodera K, Kamei J (2007) Involvement of dopa-
mine D1 receptors and a1-adrenoceptors in the antidepressant-like
effect of chlorpheniramine in the mouse tail suspension test. Eur J
Pharmacol 562:72–76. doi:10.1016/j.ejphar.2007.01.063
Hirano K, Piers TM, Searle KL, et al. (2009) Procognitive 5-HT6 antag-
onists in the rat forced swimming test: potential therapeutic utility in
mood disorders associated with Alzheimer’s disease. Life Sci 84:
558–562. doi:10.1016/j.lfs.2009.01.019
Hirst WD, Abrahamsen B, Blaney FE, et al. (2003) Differences in the
central nervous system distribution and pharmacology of the mouse
5-hydroxytryptamine-6 receptor compared with rat and human re-
ceptors investigated by radioligand binding, site-directed mutagen-
esis, and molecular modeling. Mol Pharmacol 64:1295–1308. doi:
10.1124/mol.64.6.1295
Hirst WD, Stean TO, Rogers DC, et al. (2006) SB-399885 is a potent,
selective 5-HT6 receptor antagonist with cognitive enhancing prop-
erties in aged rat water maze and novel object recognition models.
Eur J Pharmacol 553:109–119. doi:10.1016/j.ejphar.2006.09.049
Jastrzębska-Więsek M, Siwek A, Kazek G, et al. (2013) Partial agonist
efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in
vitro assays. Pharmacol Rep 65:998–1005
Jastrzębska-Więsek M, Siwek A, Partyka A, et al. (2014)
Pharmacological evaluation of the anxiolytic-like effects of EMD
386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-
maze and Vogel conflict tests. Neuropharmacology 85C:253–262.
doi:10.1016/j.neuropharm.2014.05.036
Jastrzębska-Więsek M, Siwek A, Partyka A, et al. (2015) Antidepressant-
like activity of EMD 386088, a 5-HT6 receptor partial agonist,
848 Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:839–849
following systemic acute and chronic administration to rats. Naunyn
Schmiedeberg's Arch Pharmacol:2–11. doi:10.1007/s00210-015-
1141-2
Kohen R, Metcalf MA, Khan N, et al. (1996) Cloning, characterization,
and chromosomal localization of a human 5-HT6 serotonin receptor.
J Neurochem 66:47–56
Kohen R, Fashingbauer LA, Heidmann DEA, et al. (2001) Cloning of the
mouse 5-HT6 serotonin receptor and mutagenesis studies of the
third cytoplasmic loop. Mol Brain Res 90:110–117. doi:10.1016/
S0169-328X(01)00090-0
Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA (2004) 5-HT6 recep-
tor antagonist SB-271046 enhances extracellular levels of mono-
amines in the rat medial prefrontal cortex. Synapse 51:158–164.
doi:10.1002/syn.10288
Loiseau F, Dekeyne A, Millan MJ (2008) Pro-cognitive effects of 5-HT6
receptor antagonists in the social recognition procedure in rats: im-
plication of the frontal cortex. Psychopharmacology 196:93–104.
doi:10.1007/s00213-007-0934-5
Maes M (2008) The cytokine hypothesis of depression: inflammation,
oxidative & nitrosative stress (IO&NS) and leaky gut as new targets
for adjunctive treatments in depression. Neuro Endocrinol Lett 29:
287–291
MaesM, Galecki P, Chang YS, Berk M (2011) A review on the oxidative
and nitrosative stress (O&NS) pathways in major depression and
their possible contribution to the (neuro)degenerative processes in
that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 35:676–
692. doi:10.1016/j.pnpbp.2010.05.004
Mattsson C, Sonesson C, Sandahl A, et al. (2005) 2-alkyl-3-(1,2,3,6-
tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor ago-
nists. Bioorg Med Chem Lett 15:4230–4234. doi:10.1016/j.bmcl.
2005.06.067
Monsma FJ, Shen Y, Ward RP, et al. (1993) Cloning and expression of a
novel serotonin receptor with high affinity for tricyclic psychotropic
drugs. Mol Pharmacol 43:320–327
Możdżeń E, Papp M, Gruca P, et al. (2014) 1,2,3,4-tetrahydroisoquinoline
producesanantidepressant-likeeffect intheforcedswimtestandchronic
mildstressmodelofdepressionintherat:neurochemicalcorrelates.EurJ
Pharmacol 729:107–115. doi:10.1016/j.ejphar.2014.01.075
Nikiforuk A, Kos T, Wesołowska A (2011) The 5-HT6 receptor agonist
EMD 386088 produces antidepressant and anxiolytic effects in rats
after intrahippocampal administration. Psychopharmacology 217:
411–418. doi:10.1007/s00213-011-2297-1
Popik P, Kozela E, Krawczyk M (2003) Nicotine and nicotinic receptor
antagonists potentiate the antidepressant-like effects of imipramine
and citalopram. Br J Pharmacol 139:1196–1202. doi:10.1038/sj.bjp.
0705359
Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a
primary screening test for antidepressants. Arch Int Pharmacodyn
thérapie 229:327–336
Porsolt RD, Bertin A, Jalfre M (1978) BBehavioural despair^ in rats and
mice: strain differences and the effects of imipramine. Eur J
Pharmacol 51:291–294
Riemer C, Borroni E, Levet-Trafit B, et al. (2003) Influence of the 5-HT6
receptor on acetylcholine release in the cortex: pharmacological
characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-
sulfonyl)phenylamine, a potent and selective 5-ht6 receptor antago-
nist. J Med Chem 46:1273–1276. doi:10.1021/jm021085c
Roberts JC, Reavill C, East SZ, et al. (2002) The distribution of 5-HT6
receptors in rat brain: an autoradiographic binding study using the
radiolabelled 5-HT6 receptor antagonist [125I]SB-258585. Brain
Res 934:49–57. doi:10.1016/S0006-8993(02)02360-0
Rogers MA, Bradshaw JL, Pantelis C, Phillips JG (1998) Frontostriatal
deficits in unipolar major depression. Brain Res Bull 47:297–310
Rogóz Z, Skuza G (2006) Mechanism of synergistic action following co-
treatment with pramipexole and fluoxetine or sertraline in the forced
swimming test in rats. Pharmacol Rep 58:493–500
Schechter LE, Lin Q, Smith DL, et al. (2008) Neuropharmacological
profile of novel and selective 5-HT6 receptor agonists: WAY-
181187 and WAY-208466. Neuropsychopharmacology 33:1323–
1335. doi:10.1038/sj.npp.1301503
Shytle RD, Silver AA, Lukas RJ, et al. (2002) Nicotinic acetylcholine
receptors as targets for antidepressants. Mol Psychiatry 7:525–535.
doi:10.1038/sj.mp.4001035
Stuchlik A, Rehakova L, Telensky P, Vales K (2007) Morris water maze
learning in long-Evans rats is differentially affected by blockade of
D1-like and D2-like dopamine receptors. Neurosci Lett 422:169–
174. doi:10.1016/j.neulet.2007.06.012
Svenningsson P, Tzavara ET, Qi H, et al. (2007) Biochemical and behav-
ioral evidence for antidepressant-like effects of 5-HT6 receptor stim-
ulation. J Neurosci 27:4201–4209. doi:10.1523/JNEUROSCI.3110-
06.2007
Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular
dopamine in the prefrontal cortex: a trait of drugs with antidepres-
sant potential? Psychopharmacology 115:285–288
Valentini V, Frau R, Bordi F, et al. (2011) A microdialysis study of
ST1936, a novel 5-HT6 receptor agonist. Neuropharmacology 60:
602–608. doi:10.1016/j.neuropharm.2010.12.006
Ward RP, DorsaDM (1996) Colocalization of serotonin receptor subtypes
5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J
Comp Neurol 370:405–414. doi :10.1002/(SICI)1096-
9861(19960701)370:3&lt;405::AID-CNE10&gt;3.0.CO;2-R
Ward RP, Hamblin MW, Lachowicz JE, et al. (1995) Localization of
serotonin subtype 6 receptor messenger RNA in the rat brain by in
situ hybridization histochemistry. Neuroscience 64:1105–1111. doi:
10.1016/0306-4522(94)00439-C
Wesołowska A (2007) Study into a possible mechanism responsible for
the antidepressant-like activity of the selective 5-HT6 receptor an-
tagonist SB-399885 in rats. Pharmacol Rep 59:664–671
Wesołowska A (2008) The anxiolytic-like effect of the selective 5-HT6
receptor antagonist SB-399885: the impact of benzodiazepine recep-
tors. Eur J Pharmacol 580:355–360. doi:10.1016/j.ejphar.2007.11.
022
Wesołowska A, Jastrzębska-WięsekM (2011) Behavioral pharmacology:
potential antidepressant and anxiolytic properties. Int Rev Neurobiol
96:49–71. doi:10.1016/B978-0-12-385902-0.00003-6
Wesołowska A, Nikiforuk A, Stachowicz K (2007) Anxiolytic-like and
antidepressant-like effects produced by the selective 5-HT6 receptor
antagonist SB-258585 after intrahippocampal administration to rats.
B eh a v Ph a rma co l 1 8 : 4 3 9–446 . d o i : 1 0 . 1 0 97 / FBP.
0b013e3282d28f9c
Woods S, Clarke NN, Layfield R, Fone KCF (2012) 5-HT6 receptor
agonists and antagonists enhance learning and memory in a condi-
tioned emotion response paradigm bymodulation of cholinergic and
glutamatergic mechanisms. Br J Pharmacol 167:436–449. doi:10.
1111/j.1476-5381.2012.02022.x
Woolley ML,Marsden CA, Fone KCF (2004) 5-ht6 receptors. Curr Drug
Targets CNS Neurol Disord 3:59–79
Naunyn-Schmiedeberg's Arch Pharmacol (2016) 389:839–849 849
